

# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

Date: 28/09/2018

To  
The Manager  
Listing Department  
BSE Limited  
Bombay Stock Exchange,  
P. J. Towers, Dalal Street,  
Mumbai-400001.

Ref: Scrip code 956084 and ISIN INE988W07019

**Subject:** Submission under Regulation 52(1), 52(3), 52(4) and 52(5) of Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015.


Dear Sir/Madam,

With reference to the subject matter, please find enclosed the following:

- i. The annual financial results of the Company for the financial year ended 31<sup>st</sup> March, 2018 along with the Annual Audit Report issued by the Statutory Auditors pursuant to Regulation 52(1) of SEBI (LODR), 2015.
- ii. The disclosure of the items as required under Regulation 52(4) of SEBI (LODR), 2015 (Annexure 1).
- iii. A certificate signed by debenture trustee pursuant to Regulation 52(5) of SEBI (LODR), 2015 (Annexure 2).
- iv. Declaration by Mr. Anand Shah, Compliance Officer pursuant to Regulation 52(3)(a) of the SEBI (LODR), 2015.
- v. Statement of material deviation Regulation 52(7) of SEBI (LODR), 2015.

Please take the above information on your records.

For Genlink Pharma Solutions Private Limited

  
Anand Shah  
Compliance Officer  
DIN: 00597145

# Shankarlal Jain & Associates LLP

Chartered Accountants



12, Engineer Building, 265 Princess Street, Mumbai - 400 002. India E-mail : info@sljainindia.com

Tel : +91 22 2203 6623, 2206 5739 Fax : +91 22 2208 6269 Website : www.sljainindia.com

To,

The Board of Directors,

M/S GENLINK PHARMA SOLUTIONS PRIVATE LIMITED,

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

Mumbai

Dear Sir,

Re: Auditor's Report on Yearly Financial Results as on 31st March 2018 of M/s. GENLINK PHARMA SOLUTIONS PRIVATE LIMITED, (Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED) pursuant to the Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

## Introduction

We have audited the Yearly Financial results of M/s. GENLINK PHARMA SOLUTIONS PRIVATE LIMITED, (Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED) for the year to date results for the period 1<sup>st</sup> April 2017 to 31<sup>st</sup> March 2018, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 52 of the of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. These Yearly financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the Company's Management and have been approved by the Board of Directors. Our responsibility is to express an opinion on these financial statements based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim financial Reporting (AS 25/ Ind AS 34), prescribed, under section 133 of the Companies Act, 2013 read with relevant rules issued there under; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

## Scope of Review

We conducted our audit in accordance with the Auditing Standards accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance as to whether the financial statements are free of material misstatement(s). An audit includes examining, on test basis, evidence supporting the amounts disclosed as financial result. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides reasonable basis for our opinion.



# Shankarlal Jain & Associates LLP

Chartered Accountants



12, Engineer Building, 265 Princess Street, Mumbai - 400 002. India E-mail : info@sljainindia.com

Tel : +91 22 2203 6623, 2206 5739 Fax : +91 22 2208 6269 Website : www.sljainindia.com

## Conclusion

In our opinion and to the best of our information and according to the explanations given to us these Yearly financial results to date results;

i) are presented in accordance with the requirements of Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 in this regard; and

ii) give a true and fair view of the net loss and other financial information for the year to date results for the period from 1<sup>st</sup> April 2017 to 31<sup>st</sup> March 2018.

For SHANKARLAL JAIN & ASSOCIATES LLP,  
CHARTERED ACCOUNTANTS

FIRM REG.NO:109901W/ W100082

SATISH JAIN  
PARTNER

MEMBERSHIP NO. 48874

PLACE: MUMBAI  
DATE: 28/09/2018



**GENLINK PHARMA SOLUTIONS PRIVATE LIMITED**  
**(Formerly Genlink Pharma Investments Private Limited)**

CIN No : U74110MH2016PTC280765


Regd Off. Office No - 1704, 17th Floor, Kesar Solitaire, Plot No. 5, Sector 19, Sanpada Navi Mumbai, 400705, Maharashtra, India.

**Standalone Audited Financial Results for the Year ended 31st March 2018**

INR

Sr. No.	Particulars	Year to date ended	Previous year ended
		31-Mar-18	31-Mar-17
		Audited	Audited
<b>1</b>	<b>Income from Operations</b>		
(i)	Net Sales/Income from Operations (Net of excise duty)	-	1,750,000
(ii)	Other Income	-	-
	<b>Total Income from Operations</b>	-	<b>1,750,000</b>
<b>2</b>	<b>Expenses</b>		
(i)	Cost of Material Consumed	-	-
(ii)	Purchase of Stock in trade	-	-
(iii)	Change in Inventory of Finished Goods, Work In progress and Stock in trade	-	-
(iv)	Employee Benefits Expenses	-	-
(v)	Depreciation and Amortization Expenses	-	-
(vi)	Finance Cost	18,539	1,538,265
(vii)	Other Expenses	505,728	1,894,885
	<b>Total Expenses</b>	<b>524,267</b>	<b>3,433,150</b>
<b>3</b>	<b>Profit/(Loss) from operation before tax</b>	<b>(524,267)</b>	<b>(1,683,150)</b>
<b>4</b>	<b>Tax Expenses current and deferred tax</b>	<b>30,680</b>	<b>531,830</b>
<b>5</b>	<b>Profit/(Loss) from ordinary activities for the period</b>	<b>(554,947)</b>	<b>(2,214,980)</b>
<b>6</b>	<b>Other Comprehensive Income</b>		
(i)	Items that will not be reclassified to profit or loss	-	-
(ii)	Items that will be reclassified to profit or loss	-	-
	<b>Total Comprehensive Income/(Loss) for the period</b>	<b>(554,947)</b>	<b>(2,214,980)</b>
<b>7</b>	<b>Paid up Equity Share Capital of 10/- each</b>	<b>100,000</b>	<b>100,000</b>
<b>8</b>	<b>Earning per Share(not annualised)</b>		
	Basic	-55.49	-244.99
	Diluted	-55.49	-244.99

For Genlink Pharma Solutions Private Limited



Anand Shah

Director

DIN: 00597145

Date: 28th Sept 2018

Place: Navi Mumbai

# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

CIN No : U74110MH2016PTC280765

Maharashtra, India.

## Statement of Standalone Assets & Liabilities as on 31st March, 2018

INR

Sr. No.	PARTICULARS	As On 31-Mar-18 Audited	As On 31-Mar-17 Audited
<b>ASSETS</b>			
<b>Property, plant and Equipment</b>			
1	Investment Property	-	-
2	Intangible Assets	-	-
3	Financial assets (others)	-	-
4	Non current tax assets (Net)	-	-
5	Other Non current assets	248,995,479	248,995,479
<b>Total Non-current assets</b>		<b>248,995,479</b>	<b>248,995,479</b>
<b>Current Assets</b>			
1	Financial assets	-	-
2	Investments	-	-
3	Trade and other receivables	-	-
4	Cash and cash equivalents	23,387	1,115,612
5	Other financial assets	-	-
6	Other current assets	45,198	-
<b>Total Current assets</b>		<b>68,585</b>	<b>1,115,612</b>
<b>TOTAL ASSETS</b>		<b>249,064,064</b>	<b>250,111,091</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
1	Equity Share Capital	100,000	100,000
2	Other Equity	(2,769,928)	(2,214,980)
<b>Total Equity</b>		<b>(2,669,928)</b>	<b>(2,114,980)</b>
<b>Non-current Liabilities</b>			
1	Financial liabilities	-	-
	(a) Long-term borrowings	-	-
	(b) Other Financial Liabilities	-	-
2	Long term Provision	-	-
3	Deferred Tax Liabilities (net)	250,150,000	250,000,000
4	Other Non-current Liabilities	-	-
<b>Total Non-current Liabilities</b>		<b>250,150,000</b>	<b>250,000,000</b>
<b>Current Liabilities</b>			
1	Financial Liabilities	-	-
	(a) Trade and Other payables	-	-
	(b) Other financial liabilities	-	-
2	Short term provisions	50,000	408,830
3	Other current liabilities	1,533,992	1,817,241
<b>Total Current Liabilities</b>		<b>1,583,992</b>	<b>2,226,071</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>249,064,064</b>	<b>250,111,091</b>

For Genlink Pharma Solutions Private Limited



Date: 28th Sept 2018

Anand Shah

Place: Navi Mumbai

Director

DIN: 00597145

# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

## Annexure 1

With reference to Regulation 52(4) Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015 please find the disclosure as under for the financial year ended 31<sup>st</sup> March, 2018:

1. **Credit rating** - The Company's NCDs have been rated as "SMERA BB-" by SMERA Ratings Limited. There has been no change in the credit rating of the Company.
2. **Asset cover available** - The asset cover ratio works out to more than one time on the basis of valuation of the equity shares offered as security for the NCDs.
3. **Debt-equity ratio - not applicable (due to negative net worth)**
4. **Previous due date for the payment of interest** - The Company has issued "Zero Coup" secured redeemable non-convertible debentures. Hence, no interest is required to be paid.
5. **Repayment of principal of non-convertible debt securities** - The secured redeemable non-convertible debentures are redeemable in full on September 27, 2021.
6. **Next due date for the payment of interest** - The Company has issued "Zero Coup" secured redeemable non-convertible debentures. Hence no due date is applicable.
7. **Debt service coverage ratio - not applicable (due to net loss)**
8. **Interest service coverage ratio - not applicable (due to net loss)**
9. **Outstanding redeemable preference shares (quantity and value)** - The Company does not have any outstanding redeemable preference shares
10. **Capital redemption reserve/debenture redemption reserve** - NIL
11. **Net worth** - The net worth of the Company is negative Rs. 26,69,928/-
12. **Net profit/loss after tax**  
Net loss after tax of the Company is Rs 5, 54, 947/-
13. **Earnings per share**  
Earnings per share of the Company is negative Rs 55.49/-



Office: 1704, 17<sup>th</sup> Floor, Kesar Solitaire, Plot No. 5, Sector 19, Sanpada, Navi Mumbai - 400 705, India  
Ph: +91 22 6750 7000 Fax +91 22 6750 7070 Email [genlinkinfo@gmail.com](mailto:genlinkinfo@gmail.com) [www.genlinkpharma.com](http://www.genlinkpharma.com)

CIN: U74110 MH 2016 PTC 280765

October 01, 2018

To  
**Mr. Anand Shah,**  
**Compliance Officer,**  
**Genlink Pharma Solutions Private Limited**  
**1704, 17th Floor, Kesar Solitaire,**  
**Plot No. 5, Sector 19,**  
**Sanpada, Navi Mumbai - 400 705,**  
**Maharashtra, India.**

**Ref:** Scrip code 956084 and ISIN INE988W07019

**Subject:** Certificate of Debenture Trustee under Regulation 52(5) of SEBI (LODR), 2015 for the financial year ended 31<sup>st</sup> March, 2018.

In compliance with the requirement of Chapter V, Regulation 52(4) and 52(5) of the Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015 for Secured Redeemable Non-Convertible Debentures it is certified as under:

We, Vistra ITCL (India) Limited are acting as a Debenture Trustee for the debenture programme of Rated, Listed, Redeemable, Non-Convertible Debentures (NCDs) issue aggregating to Rs. 25 Crores of Genlink Pharma Solutions Private Limited (formerly known as Genlink Pharma Investments Private Limited), "the Company"

With reference to the above, we have received the following documents and noted its contents:

1. Audited financial results for the year ended 31<sup>st</sup> March, 2018 along with Audit report for the year ended 31<sup>st</sup> March, 2018.
2. Disclosure pursuant to Regulation 52(4) of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 for the financial year ended 31<sup>st</sup> March, 2018.

This certificate has been signed and issued by us based on documents (mentioned above) submitted by you.

Thanking You.

Yours sincerely,  
**For Vistra ITCL (India) Limited**

  
**Authorized signatory**

**Place: Mumbai**

# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

Date: 28/09/2018

To  
The Manager  
Listing Department  
BSE Limited  
Bombay Stock Exchange,  
P. J. Towers, Dalal Street,  
Mumbai-400001.

Subject: Declaration pursuant to Regulation 52(3)(a) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Scrip Code: Scrip code 956084 and ISIN INE988W07019

Dear Sir/Madam,

Pursuant to Regulation 52(3)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, I, Anand Shah, Director and Compliance Officer of Genlink Pharma Solutions Private Limited (Formerly Known as Genlink Pharma Investments Private Limited) (CIN: U74110MH2016PTC280765), having its Registered Office at Office No - 1704, 17<sup>th</sup> Floor, Kesar Solitaire, Plot No. 5, Sector 19, Sanpada, Navi Mumbai - 400705, Maharashtra, India, do hereby declare that, the Statutory Auditors of the Company, Shankarlal Jain & Associates LLP, Chartered Accountants (FRN 109901W/W100082) have issued an Audit Report with an unmodified opinion on the Audited Financial Results of the Company for the year ended March 31, 2018.

Kindly take this declaration on record.

Yours faithfully,

For Genlink Pharma Solutions Private Limited



Anand Shah  
DIN: 00597145  
Director & Compliance Officer



# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

Date: 28/09/2018

To  
The Manager  
Listing Department  
BSE Limited  
Bombay Stock Exchange,  
P. J. Towers, Dalal Street,  
Mumbai-400001

Ref: Scrip code 956084 and ISIN INE988W07019


**Subject:** Statement of material deviation under Regulation 52(7) Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015

Dear Sir/Madam,

With reference to Regulation 52(7) Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015 we hereby state that for the year ended 31<sup>st</sup> March, 2018, there is no material deviation in the use of proceeds of Secured Redeemable Non-Convertible Debentures from the objects stated in the offer document.

Please take the above information on your records.

For Genlink Pharma Solutions Private Limited



Anand Shah  
Compliance Officer  
DIN: 00597145

# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

Date: 28/09/2018

To  
The Manager  
Listing Department  
BSE Limited  
Bombay Stock Exchange,  
P. J. Towers, Dalal Street,  
Mumbai-400001

Ref: Scrip code 956084 and ISIN INE988W07019

**Subject:** Submission under Regulation 54(2) of Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015.

Dear Sir/Madam,

With reference to the subject matter, please note that the Company maintains for the financial year ended 31<sup>st</sup> March, 2018 hundred percent asset cover sufficient to discharge the principal amount at all times for the non-convertible debt securities issued.

The details of extent and nature of security created and maintained with respect to its listed secured non-convertible redeemable debt securities are as follows:

1. 4,13,497 Equity shares of Enaltec Labs Pvt. Ltd. held by the Company.
2. 80,923 Equity shares of Enaltec Labs Pvt. Ltd. held by Mr. Anand Shah.
3. 80,923 Equity shares of Enaltec Labs Pvt. Ltd. held by Mr. Susheel Koul.

Please take the above information on your records.

For Genlink Pharma Solutions Private Limited



Anand Shah  
Compliance Officer  
DIN: 00597145